Presentation

Gentian Diagnostics develops and manufactures high quality in vitro diagnostic reagents with focus lies within immunochemistry, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian serves the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Recent highlights
In Q1, total revenue amounted to 23.1M NOK, with sales revenue amounted to 20.6M NOK.
In January, Gentian announced a global distribution contract for the Gentian Calprotectin Immunoassay GCAL® with Siemens Healthineers. The GCAL® assay will be offered on the Siemens Healthineers BN™ II, BN ProSpec®, and Atellica® NEPH platforms and positioned toward the rheumatoid arthritis market, with launch scheduled for H2 2022. In March, Gentian announced the release of the novel CE marked SARS-CoV-2 Total Antibody Immunoassay. In April, Gentian signed a distribution agreement for its Cystatin C Immunoassay with one of the world’s largest global diagnostics companies and covers the US, a key growth market for Cystatin C.

Outlook
By the end of 2022, Gentian aims to target additional large commercial partners and secure additional regulatory approvals, including IVDR, for its established products. For the GCAL program, Gentian aims to secure global commercial partners, continue EU rollout, and continue clinical study. With commercial launch of SARS-COV-2 AB in March, Gentian is initiating rollout with focus on the Nordics. Lastly, for NT-PROBNP, the company aims to progress on remaining challenges in optimisation phase, secure endorsements from KOL, and build commercial interest for the product.